---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-26-023352"
form_type: "8-K"
ticker: "PAVM"
cik: "0001624326"
company_name: "PAVmed Inc."
filed_at: "2026-05-15T12:05:34+00:00"
generated_at: "2026-05-15T12:12:27.220445+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# PAVmed Q1 GAAP net loss $7.0M; Lucid Diagnostics revenue $1.3M, 3,177 tests

## Summary
- GAAP net loss $7.0M ($4.42 diluted EPS); non-GAAP adjusted loss $1.9M ($1.17 per share).
- Cash and equivalents $6.5M at Mar 31, up from $1.5M at Dec 31, 2025.
- Lucid Diagnostics Q1 EsoGuard revenue $1.3M, 3,177 tests processed; raised $17M in public offering, proforma cash $45M.
- Veris Health advancing implantable physiological monitor towards FDA 510(k) submission.
- PAVmed relaunched medical device portfolio including PortIO and Duke-licensed endoscopic imaging.

## SEC filing metadata
- accession: 0001493152-26-023352
- form_type: 8-K
- ticker: PAVM
- cik: 0001624326
- company_name: PAVmed Inc.
- filed_at: 2026-05-15T12:05:34+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/0001493152-26-023352-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-26-023352
- JSON: https://secwatch.observer/filing/0001493152-26-023352.json
- Plain text: https://secwatch.observer/filing/0001493152-26-023352.txt

## Key facts
- Earnings Releases
  PAVmed Inc. reported first quarter ended March 31, 2026 results: net income approximately $7.0 million, EPS $(4.42) per common share on a diluted basis.
  - Period: first quarter ended March 31, 2026
  - Net income: approximately $7.0 million
  - EPS: $(4.42) per common share on a diluted basis
  - Result: reported results
  source text: On May 15, 2026, PAVmed Inc. (the “ Company ”) issued a press release announcing financial results for its fiscal quarter ended March 31, 2026
  evidence_url: https://www.sec.gov/Archives/edgar/data/1624326/000149315226023352/0001493152-26-023352-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.